Cargando…
Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy
BACKGROUND: Many drugs with dose-dependent effects on hemodynamic variables are metabolized by cytochrome P450 2D6 (CYP2D6). The aim of this study was to compare prescribed dosages and hemodynamic responses of such drugs in relation to pharmacogenetic variability in CYP2D6 metabolism among patients...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272489/ https://www.ncbi.nlm.nih.gov/pubmed/32346827 http://dx.doi.org/10.1007/s40266-020-00763-0 |
_version_ | 1783542265838305280 |
---|---|
author | Romskaug, Rita Wyller, Torgeir Bruun Straand, Jørund Kersten, Hege Molden, Espen |
author_facet | Romskaug, Rita Wyller, Torgeir Bruun Straand, Jørund Kersten, Hege Molden, Espen |
author_sort | Romskaug, Rita |
collection | PubMed |
description | BACKGROUND: Many drugs with dose-dependent effects on hemodynamic variables are metabolized by cytochrome P450 2D6 (CYP2D6). The aim of this study was to compare prescribed dosages and hemodynamic responses of such drugs in relation to pharmacogenetic variability in CYP2D6 metabolism among patients aged ≥ 70 years exposed to polypharmacy. MATERIALS AND METHODS: We included 173 patients with detailed information about drug use. The patients were retrospectively subjected to CYP2D6 genotyping, which comprised the most common variant alleles encoding reduced, absent, or increased CYP2D6 metabolism. In order to compare dosages across different CYP2D6-metabolized drugs, all prescribed daily doses were harmonized to the ‘percent of a daily defined dose’ (DDD). The mean harmonized DDD was compared between genotype-predicted normal metabolizers (NMs) and patients with reduced or absent CYP2D6 enzyme activity, defined as intermediate or poor metabolizers (IMs/PMs). Blood pressure, pulse, and patient proportions with orthostatism and bradycardia were also compared between genotype subgroups. RESULTS: The genotype-predicted phenotype subgroups comprised 79 NMs (45.7%), 75 IMs (43.4%), and 16 PMs (9.2%). There were no differences in dosing of CYP2D6 substrates between NMs and IMs/PMs (p = 0.76). A higher proportion of CYP2D6 IMs/PMs experienced orthostatism (p = 0.03), while there were no significant subgroup differences for the other hemodynamic variables. CONCLUSION: In this real-life clinical setting of patients aged ≥ 70 years, dosing of CYP2D6 substrates were not adjusted according to genotype-predicted CYP2D6 metabolism. The increased occurrence of orthostatism in patients with reduced/absent CYP2D6 metabolism may indicate that individualized dosing based on genotype has the potential to prevent adverse effects in these vulnerable patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40266-020-00763-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7272489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-72724892020-06-15 Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy Romskaug, Rita Wyller, Torgeir Bruun Straand, Jørund Kersten, Hege Molden, Espen Drugs Aging Short Communication BACKGROUND: Many drugs with dose-dependent effects on hemodynamic variables are metabolized by cytochrome P450 2D6 (CYP2D6). The aim of this study was to compare prescribed dosages and hemodynamic responses of such drugs in relation to pharmacogenetic variability in CYP2D6 metabolism among patients aged ≥ 70 years exposed to polypharmacy. MATERIALS AND METHODS: We included 173 patients with detailed information about drug use. The patients were retrospectively subjected to CYP2D6 genotyping, which comprised the most common variant alleles encoding reduced, absent, or increased CYP2D6 metabolism. In order to compare dosages across different CYP2D6-metabolized drugs, all prescribed daily doses were harmonized to the ‘percent of a daily defined dose’ (DDD). The mean harmonized DDD was compared between genotype-predicted normal metabolizers (NMs) and patients with reduced or absent CYP2D6 enzyme activity, defined as intermediate or poor metabolizers (IMs/PMs). Blood pressure, pulse, and patient proportions with orthostatism and bradycardia were also compared between genotype subgroups. RESULTS: The genotype-predicted phenotype subgroups comprised 79 NMs (45.7%), 75 IMs (43.4%), and 16 PMs (9.2%). There were no differences in dosing of CYP2D6 substrates between NMs and IMs/PMs (p = 0.76). A higher proportion of CYP2D6 IMs/PMs experienced orthostatism (p = 0.03), while there were no significant subgroup differences for the other hemodynamic variables. CONCLUSION: In this real-life clinical setting of patients aged ≥ 70 years, dosing of CYP2D6 substrates were not adjusted according to genotype-predicted CYP2D6 metabolism. The increased occurrence of orthostatism in patients with reduced/absent CYP2D6 metabolism may indicate that individualized dosing based on genotype has the potential to prevent adverse effects in these vulnerable patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40266-020-00763-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-04-29 2020 /pmc/articles/PMC7272489/ /pubmed/32346827 http://dx.doi.org/10.1007/s40266-020-00763-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Short Communication Romskaug, Rita Wyller, Torgeir Bruun Straand, Jørund Kersten, Hege Molden, Espen Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title | Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title_full | Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title_fullStr | Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title_full_unstemmed | Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title_short | Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy |
title_sort | prescribed doses of cyp2d6-metabolized drugs and hemodynamic responses in relation to cyp2d6 genotype among older patients exposed to polypharmacy |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272489/ https://www.ncbi.nlm.nih.gov/pubmed/32346827 http://dx.doi.org/10.1007/s40266-020-00763-0 |
work_keys_str_mv | AT romskaugrita prescribeddosesofcyp2d6metabolizeddrugsandhemodynamicresponsesinrelationtocyp2d6genotypeamongolderpatientsexposedtopolypharmacy AT wyllertorgeirbruun prescribeddosesofcyp2d6metabolizeddrugsandhemodynamicresponsesinrelationtocyp2d6genotypeamongolderpatientsexposedtopolypharmacy AT straandjørund prescribeddosesofcyp2d6metabolizeddrugsandhemodynamicresponsesinrelationtocyp2d6genotypeamongolderpatientsexposedtopolypharmacy AT kerstenhege prescribeddosesofcyp2d6metabolizeddrugsandhemodynamicresponsesinrelationtocyp2d6genotypeamongolderpatientsexposedtopolypharmacy AT moldenespen prescribeddosesofcyp2d6metabolizeddrugsandhemodynamicresponsesinrelationtocyp2d6genotypeamongolderpatientsexposedtopolypharmacy |